Literature DB >> 27499137

The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.

S L Locatelli1, G Careddu1, G Inghirami2,3,4, L Castagna1, P Sportelli5, A Santoro1,6, C Carlo-Stella1,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27499137     DOI： 10.1038/leu.2016.224

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

Review 1.  Microtubule-targeted anticancer agents and apoptosis.

Authors:  Kapil N Bhalla
Journal:  Oncogene       Date:  2003-12-08       Impact factor: 9.867

2.  G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells.

Authors:  April L Blajeski; Vy A Phan; Timothy J Kottke; Scott H Kaufmann
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

Authors:  Sarah A Meadows; Francisco Vega; Adam Kashishian; Dave Johnson; Volker Diehl; Langdon L Miller; Anas Younes; Brian J Lannutti
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

4.  Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma--can they make one of medical oncology's chemotherapy success stories more successful?

Authors:  George P Canellos
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

5.  Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.

Authors:  Amanda Dutton; Gary M Reynolds; Christopher W Dawson; Lawrence S Young; Paul G Murray
Journal:  J Pathol       Date:  2005-03       Impact factor: 7.996

Review 6.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

7.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

Review 8.  Beyond chemotherapy: new agents for targeted treatment of lymphoma.

Authors:  Anas Younes
Journal:  Nat Rev Clin Oncol       Date:  2010-12-14       Impact factor: 66.675

9.  CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

Authors:  Brian J Lannutti; Sarah A Meadows; Sarah E M Herman; Adam Kashishian; Bart Steiner; Amy J Johnson; John C Byrd; Jeffrey W Tyner; Marc M Loriaux; Mike Deininger; Brian J Druker; Kamal D Puri; Roger G Ulrich; Neill A Giese
Journal:  Blood       Date:  2010-10-19       Impact factor: 22.113

Review 10.  Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.

Authors:  Antonino Carbone; Annunziata Gloghini; Luca Castagna; Armando Santoro; Carmelo Carlo-Stella
Journal:  J Pathol       Date:  2015-06-03       Impact factor: 7.996
View more
  5 in total

Review 1.  PI3K signaling in cancer: beyond AKT.

Authors:  Evan C Lien; Christian C Dibble; Alex Toker
Journal:  Curr Opin Cell Biol       Date:  2017-03-24       Impact factor: 8.382

Review 2.  Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Authors:  Jan A Burger; Adrian Wiestner
Journal:  Nat Rev Cancer       Date:  2018-01-19       Impact factor: 60.716

3.  Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.

Authors:  Theodoros Karantanos; Ioannis Politikos; Vassiliki A Boussiotis
Journal:  Blood Lymphat Cancer       Date:  2017-05-09

4.  The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.

Authors:  Matthew T Villaume; M Pia Arrate; Haley E Ramsey; Kathryn I Sunthankar; Matthew T Jenkins; Tamara K Moyo; Brianna N Smith; Melissa A Fischer; Merrida A Childress; Agnieszka E Gorska; P Brent Ferrell; Michael R Savona
Journal:  Exp Hematol       Date:  2021-02-19       Impact factor: 3.249

Review 5.  Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.

Authors:  Ningni Jiang; Qijie Dai; Xiaorui Su; Jianjiang Fu; Xuancheng Feng; Juan Peng
Journal:  Mol Biol Rep       Date:  2020-04-24       Impact factor: 2.742
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.